Royal Bank of Canada
NBIX icon

Royal Bank of Canada’s Neurocrine Biosciences NBIX Stock Holding History

Royal Bank of Canada’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-139,000
Closed -$1.86M – 6200
2013
Q2 		$1.86M Buy
+139,000
New +$1.71M ﹤0.01% 2111

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada's NBIX Position: Q2 2026 in Review

Royal Bank of Canada increased its Neurocrine Biosciences (NBIX) stake by 76% in Q2 2026, buying an estimated $37.3M and bringing the position to 583,476 shares worth $98.3M. The position accounts for 0.01% of the portfolio, ranked #707.

Royal Bank of Canada first reported a position in NBIX in Q2 2013 and has held it in 53 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Royal Bank of Canada held 583,476 shares of Neurocrine Biosciences worth $98.3M as of Q2 2026.
  • Royal Bank of Canada bought 251,176 Neurocrine Biosciences shares in Q2 2026, an estimated $37.3M.
  • Neurocrine Biosciences made up 0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #707 holding.
  • Royal Bank of Canada first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 53 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.